ORR and reduction in lymph node SPD with single-agent ibrutinib treatment. (A) Response rates for total efficacy population and by prior line of therapy. (B) Best response over time in the total efficacy population (n = 60). (C) Change in tumor size by prior line of therapy in the ITT population. *Patients in the “Other” category had prior treatment with both single-agent RTX and chemotherapy or investigational therapies. †Four patients who discontinued before the first response assessment were excluded. PD, progression of disease; SD, stable disease.